A case series reports dysesthesia and allodynia in patients treated with semaglutide and tirzepatide, suggesting a possible dose related to sensory adverse effect.
ACHIEVE-3 randomized 1698 metformin-treated adults with inadequately controlled type 2 diabetes to once-daily orforglipron ...
A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...
Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30 million reports from the FDA Adverse ...
MedPage Today on MSN
Novel GLP-1 Pill Tops Oral Semaglutide for Diabetes
Orforglipron carried more side effects, however ...
This report describes a female patient in her 60s with an immune-mediated necrotising myopathy (IMNM) occurring after semaglutide use. She was found to have progressive dysphagia, dysphonia, proximal ...
Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), ...
The findings add to competitive pressure on Novo Nordisk’s GLP-1 portfolio and come days after the Danish drugmaker reported that its next-generation obesity drug, CagriSema, did not meet its primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results